Apellis Pharmaceuticals (APLS) shares were up 4% in recent trading Monday after the company reported preliminary full-year 2024 US net product revenue of $709 million for Syfovre and Empaveli.
Analysts polled by FactSet expected 2024 combined sales of $710 million for the two products.
The company said the preliminary figure includes Syfovre sales of about $167 million in Q4 and $611 million in 2024. Analysts surveyed by FactSet were looking for Q4 sales of $157.1 million for the company's product for the treatment of geographic atrophy secondary to age-related macular degeneration, with full-year sales expected to hit $604.9 million.
Apellis reported about $23 million in preliminary Q4 sales for Empaveli, bringing full-year sales of the medicine for adults with paroxysmal nocturnal hemoglobinuria to $98 million. Analysts polled by FactSet expected $26.2 million for Q4 and $105.1 million for the year.
The company said it had roughly $410 million in cash and cash equivalents at the end of 2024, up from $351.2 million a year earlier, which together with projected revenue will be sufficient to fund its operating expenses and capital expenditures to profitability.
Price: 28.56, Change: +1.12, Percent Change: +4.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.